医学
免疫组织化学
PD-L1
CTLA-4号机组
乳腺癌
内科学
肿瘤科
肿瘤浸润淋巴细胞
抗体
免疫系统
免疫检查点
癌症
T细胞
免疫学
免疫疗法
作者
Balázs Ács,Lilla Madaras,Anna‐Mária Tőkés,Attila Kristóf Kovács,Erzsébet Kovács,Magdolna Ozsvári-Vidákovich,Ádám Karászi,Ede Birtalan,Magdolna Dank,Attila Marcell Szász,Janina Kulka
出处
期刊:The Breast
[Elsevier]
日期:2017-06-24
卷期号:35: 69-77
被引量:24
标识
DOI:10.1016/j.breast.2017.06.013
摘要
Purpose We aimed to compare the immunohistochemical expression of PD-1, PD-L1 and CTLA-4 of pregnancy-related breast cancer (PRBC) and early onset non-PRBC (YWBC), and their prognosis prediction potential was correlated to that of conventional clinicopathological factors. Methods Twenty-one PRBC cases were paired with 21 YWBC in this matched case-control study. Immune-checkpoint markers (ICM) were evaluated with immunohistochemistry (IHC) on whole slides using the following antibodies: PD-1 (NAT-105), PD-L1 (28-8) and CTLA-4 (F-8). IHC score was defined as the percentage of positive cells, assessed separately among tumor cells, intratumoral lymphocytes and peritumoral lymphocytes. Results The optimal threshold of PD-L1 expression of tumor cells occurred at 10% for overall survival (OS, AUC = 0.847, p = 0.009), and at 1% for disease-free survival (DFS, AUC = 0.795, p = 0.010). For PD-L1 expression on intratumoral lymphocytes, the optimal cut-off was 1% (AUC = 0.763, p = 0.048). Considering PD-1, PD-L1 and CTLA-4 expression, no significant difference occurred between PRBC and YWBC (p > 0.05 for all comparisons). PD-1, PD-L1 expressed on peritumoral lymphocytes and CTLA-4 failed, but PD-L1 expressed on tumor cells and on intratumoral lymphocytes was suitable to distinguish patient cohorts with different OS and DFS (p ≤ 0.011 for all comparisons). Higher PD-L1 expression was associated with poor prognosis. PD-L1 expressed on tumor cells represented an independent association with OS (p = 0.023) and DFS (p = 0.032). Conclusions Our results suggest that PRBC and YWBC do not differ in the expression of PD-1, PD-L1 and CTLA-4. However, our findings emphasize the relevance of PD-L1 expression in early-onset breast cancer, as an independent negative predictor of prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI